Deutsche Bank AG Buys Shares of 230,787 CeriBell (NASDAQ:CBLL)

Deutsche Bank AG purchased a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 230,787 shares of the company's stock, valued at approximately $5,973,000. Deutsche Bank AG owned about 0.64% of CeriBell as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in CeriBell during the fourth quarter worth approximately $32,000. Summit Investment Advisors Inc. bought a new position in shares of CeriBell during the fourth quarter worth approximately $33,000. Tower Research Capital LLC TRC bought a new position in shares of CeriBell during the fourth quarter worth approximately $37,000. BNP Paribas Financial Markets bought a new position in shares of CeriBell during the fourth quarter worth approximately $43,000. Finally, PNC Financial Services Group Inc. bought a new position in shares of CeriBell during the fourth quarter worth approximately $47,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CBLL. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.50.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 3,372 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $15.03, for a total value of $50,681.16. Following the sale, the chief executive officer now owns 743,079 shares of the company's stock, valued at approximately $11,168,477.37. This trade represents a 0.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 49,700 shares of company stock valued at $796,434. 20.10% of the stock is currently owned by corporate insiders.

CeriBell Trading Down 1.7%

NASDAQ:CBLL traded down $0.29 during trading hours on Thursday, reaching $17.26. 252,544 shares of the company were exchanged, compared to its average volume of 277,564. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The business has a 50 day moving average of $17.29 and a 200 day moving average of $22.26.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. On average, research analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.